Replacing oxytropium with tiotropium significantly improves pulmonary function in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006
Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms & morning activities in COPD patients Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Source: Eur Respir J 2002; 19: 209-216 Year: 2002
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020
Compliance of inhalation medication in relation to illness perception, quality of life and predicted pulmonary function in COPD patients Source: Annual Congress 2010 - Advances in lung function II Year: 2010
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Relationship between severity of bronchial and systemic inflammation, and dyspnea, exercise performance and quality of life in patients with stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006
The effect of different bronchodilator drugs on pulmonary function tests, exercise capacity and quality of life in patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 515s Year: 2005
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Long-term changes in lung function, dyspnea and exercise capacity in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 490s Year: 2002
Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001
Correlation between indices of quality of life and degree of severity of symptoms in patients with asthma in combination with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 520s Year: 2004
The improvements of lung function tests after formoterol administration in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 323s Year: 2004
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Pretreatment with inhaled procaterol improves symptoms of dyspnea and quality of life in patients with severe COPD Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Lung function indices versus symptoms for monitoring the course of the disease in patients with COPD Source: Annual Congress 2008 - Functionality and metabolism in rehabilitation candidates Year: 2008